​

IDEXX Laboratories (IDXX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IDXX Stock Forecast

IDEXX Laboratories (IDXX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $479.75, with a high of $600.00 and a low of $247.00. This represents a 12.44% increase from the last price of $426.69.

$200 $280 $360 $440 $520 $600 High: $600 Avg: $479.75 Low: $247 Last Closed Price: $426.69

IDXX Stock Rating

IDEXX Laboratories stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

IDXX Price Target Upside V Benchmarks

TypeNameUpside
StockIDEXX Laboratories12.44%
SectorHealthcare Stocks 25.49%
IndustryDiagnostics & Research Stocks28.80%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$510.00
Last Closing Price$426.69$426.69$426.69
Upside/Downside--19.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 25436-114
Feb, 25437-115
Jan, 25436-114
Dec, 24436-215
Nov, 244251214
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 24, 2024Jonathan BlockStifel Nicolaus$510.00$495.732.88%19.52%
Feb 08, 2023Barclays$590.00$507.6816.21%38.27%
Feb 07, 2023J.P. Morgan$550.00$487.0412.93%28.90%
Feb 07, 2023Atlantic Equities$600.00$485.5323.58%40.62%
Feb 02, 2023Oppenheimer$247.00$483.20-48.88%-42.11%
Feb 02, 2023Citigroup$268.00$483.20-44.54%-37.19%
Dec 09, 2022Citigroup$273.00$420.63-35.10%-36.02%
Nov 15, 2022Morgan Stanley$543.00$435.7824.60%27.26%
Jun 24, 2022Stifel Nicolaus$500.00$355.6240.60%17.18%
May 19, 2022Goldman Sachs$530.00$357.3348.32%24.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2025BarclaysOverweightOverweighthold
Jul 25, 2024BTIGBuyinitialise
Feb 08, 2023BarclaysOverweightOverweighthold
Feb 07, 2023Atlantic EquitiesOverweightOverweighthold
Feb 02, 2023OppenheimerOutperformOutperformhold
Feb 02, 2023CitigroupBuyBuyhold
Dec 09, 2022CitigroupBuyBuyhold
Nov 15, 2022Morgan StanleyOverweightOverweighthold
Jul 21, 2022Goldman SachsNeutralBuyupgrade
May 19, 2022Goldman SachsNeutralNeutralhold

Financial Forecast

EPS Forecast

$5 $8 $11 $14 $17 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.82$8.74$8.12$10.17$10.79----
Avg Forecast$6.10$8.38$7.91$9.86$10.46$11.97$13.55$15.48$16.93
High Forecast$6.19$8.50$7.99$9.92$10.54$12.22$14.03$16.33$17.13
Low Forecast$6.04$8.30$7.82$9.81$10.40$11.75$12.84$14.21$16.70
Surprise %11.80%4.30%2.65%3.14%3.15%----

Revenue Forecast

$3B $3B $4B $4B $5B $6B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.71B$3.22B$3.37B$3.66B$3.90B----
Avg Forecast$2.67B$3.19B$3.36B$3.65B$3.88B$4.15B$4.51B$4.95B$5.39B
High Forecast$2.70B$3.23B$3.38B$3.66B$3.89B$4.18B$4.52B$4.95B$5.44B
Low Forecast$2.65B$3.17B$3.33B$3.64B$3.84B$4.12B$4.50B$4.94B$5.34B
Surprise %1.49%0.65%0.28%0.33%0.49%----

Net Income Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$581.78M$744.85M$679.09M$845.04M$887.87M----
Avg Forecast$418.39M$604.02M$662.67M$845.04M$878.93M$1.01B$1.10B$1.22B$1.42B
High Forecast$502.06M$724.83M$795.20M$1.01B$884.81M$1.03B$1.18B$1.37B$1.44B
Low Forecast$334.71M$483.22M$530.13M$676.03M$873.04M$986.97M$1.08B$1.19B$1.40B
Surprise %39.05%23.31%2.48%-1.02%----

IDXX Forecast FAQ

Is IDEXX Laboratories stock a buy?

IDEXX Laboratories stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IDEXX Laboratories is a favorable investment for most analysts.

What is IDEXX Laboratories's price target?

IDEXX Laboratories's price target, set by 7 Wall Street analysts, averages $479.75 over the next 12 months. The price target range spans from $247 at the low end to $600 at the high end, suggesting a potential 12.44% change from the previous closing price of $426.69.

How does IDEXX Laboratories stock forecast compare to its benchmarks?

IDEXX Laboratories's stock forecast shows a 12.44% upside, underperforming the average forecast for the healthcare stocks sector (25.49%) and underperforming the diagnostics & research stocks industry (28.80%).

What is the breakdown of analyst ratings for IDEXX Laboratories over the past three months?

  • March 2025: 28.57% Strong Buy, 21.43% Buy, 42.86% Hold, 0% Sell, 7.14% Strong Sell.
  • February 2025: 26.67% Strong Buy, 20.00% Buy, 46.67% Hold, 0% Sell, 6.67% Strong Sell.
  • January 2025: 28.57% Strong Buy, 21.43% Buy, 42.86% Hold, 0% Sell, 7.14% Strong Sell.

What is IDEXX Laboratories’s EPS forecast?

IDEXX Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $11.97, marking a 10.94% increase from the reported $10.79 in 2024. Estimates for the following years are $13.55 in 2026, $15.48 in 2027, and $16.93 in 2028.

What is IDEXX Laboratories’s revenue forecast?

IDEXX Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $4.15B, reflecting a 6.58% increase from the reported $3.9B in 2024. The forecast for 2026 is $4.51B, followed by $4.95B for 2027, and $5.39B for 2028.

What is IDEXX Laboratories’s net income forecast?

IDEXX Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $1.01B, representing an 13.38% increase from the reported $887.87M in 2024. Projections indicate $1.1B in 2026, $1.22B in 2027, and $1.42B in 2028.